An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in pati...
An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis
About this item
Full title
Author / Creator
Publisher
Hoboken: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
The efficacy of ponesimod and teriflunomide for the treatment of relapsing multiple sclerosis (MS) was compared in a randomized phase III trial. This study explores the exposure‐response (E‐R) relationships of efficacy end points (annualized relapse rate [ARR] and combined unique active lesions [CUALs]) of ponesimod observed in this trial. The E‐R...
Alternative Titles
Full title
An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_531afc9bc7ca4e63b7b43fe2aa37c10f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_531afc9bc7ca4e63b7b43fe2aa37c10f
Other Identifiers
ISSN
2163-8306
E-ISSN
2163-8306
DOI
10.1002/psp4.12778
